I need authoratitive data showing the proportion of new
medicines that make it to market and where in the development process
they drop out.  From memory, there's a lot go at Phase I/II due to
lack of efficacy or side effects.

I don't need a long answer, but I need it quite quickly and it does
need to be a decently authoratitive source (FDA, MCA, well-conducted
research study).

I already have the pharmaceutical investment and output survey.

I need the info by end of the weekend (Sunday 16th May)

Thanks

Poet

---

Request for Question Clarification by pinkfreud-ga on 13 May 2004 11:42 PDT

This data comes from the Centre for Medical Research International:

"For any company to get a return on its R&D investment, its products
have to reach the marketplace. The probability of a NME [New Molecular
Entity] in development reaching the market increases with each
successive phase of the R&D process, but the route is far from easy
(Graph 5). CMR International?s latest attrition data suggests that
only 15% of NMEs entering development subsequently reach the market.
Success rates from phase III to market range between 50% and 70%5.
These high attrition rates are a major challenge for the industry in
the face of demands for increased productivity of NMEs."

http://www.cmr.org/pdfs/springnews2002.pdf

Does this meet your needs?

---

Clarification of Question by poet-ga on 14 May 2004 13:25 PDT

Dear Pionfreud

Yes that's great...please post the link as an answer...nothing further required.

Ta

Poet

I'm glad the material I found met your needs. I've reposted the link below.

"For any company to get a return on its R&D investment, its products
have to reach the marketplace. The probability of a NME [New Molecular
Entity] in development reaching the market increases with each
successive phase of the R&D process, but the route is far from easy
(Graph 5). CMR International?s latest attrition data suggests that
only 15% of NMEs entering development subsequently reach the market.
Success rates from phase III to market range between 50% and 70%5.
These high attrition rates are a major challenge for the industry in
the face of demands for increased productivity of NMEs."

Centre for Medical Research International
http://www.cmr.org/pdfs/springnews2002.pdf

Best regards,
pinkfreud